Plain-English translation of NCT06969807 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called , which is made from special cells collected from umbilical cord tissue. These stem cells may help repair kidney damage and reduce protein loss in the urine for people with diabetic kidney disease. Researchers want to see if this medication can improve how well your kidneys work and reduce the amount of protein your kidneys leak into your urine.
Diabetic kidney disease is a serious complication of diabetes that can eventually lead to kidney failure. Current standard treatments help slow the damage, but they don't always stop it completely. This trial is testing whether stem cell therapy could offer additional benefit by helping to repair and regenerate damaged kidney tissue.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will continue your regular diabetes and kidney disease medications while also receiving infusions of the stem cell treatment. You will receive six infusions over a 24-week period (roughly 6 months) — the first three spaced 2 weeks apart, then additional doses at weeks 8, 12, 16, 20, and 24. During the study, you will have blood and urine tests to monitor how your kidneys respond to the treatment.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
China